You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameIsosorbide Mononitrate
Accession NumberDB01020  (APRD00528)
TypeSmall Molecule
GroupsApproved
Description

Isosorbide mononitrate is a drug used principally in the treatment of angina pectoris1 and acts by dilating the blood vessels so as to reduce the blood pressure. It is sold by AstraZeneca under the trade name Imdur.

Isosorbide mononitrate is used to for the the prophylactic treatment of angina pectoris; that is, it is taken in order to prevent or at least reduce the occurrence of angina. Research on Isosorbide mononitrate as a cervical ripener to reduce time at hospital to birth is supportive.

Isosorbide mononitrate is an active metabolite of isosorbide dinitrate and exerts qualitatively similar effects. Isosorbide mononitrate reduces the workload of the heart by producing venous and arterial dilation. By reducing the end diastolic pressure and volume, isosorbide mononitrate lowers intramural pressure, hence leading to an improvement in the subendocardial blood flow. The net effect when administering isosorbide mononitrate is therefore a reduced workload for the heart and an improvement in the oxygen supply/demand balance of the myocardium.

The adverse reactions which follow have been reported in studies with isosorbide mononitrate:
Very common. Headache predominates (up to 30%) necessitating withdrawal of 2 to 3 % of patients, but the incidence reduces rapidly as treatment continues .
Common. Tiredness, sleep disturbances (6%) and gastrointestinal disturbances (6%) have been reported during clinical trials with isosorbide mononitrate modified release tablets, but at a frequency no greater than for placebo. Hypotension (4 to 5%), poor appetite (2.5%), nausea (1%).
Adverse effects associated with the clinical use of the drug are as expected with all nitrate preparations. They occur mainly in the early stages of treatment.
Hypotension (4%) with symptoms such as dizziness and nausea (1%) have been reported. These symptoms generally disappear during long-term treatment.
Other reactions that have been reported with isosorbide mononitrate modified release tablets include tachycardia, vomiting, diarrhoea, vertigo and heartburn

Structure
Thumb
Synonyms
Corangin
Duride
Elantan
Imdur
Imtrate
Ismexin
Ismo
Ismox
Isosorbide mononitrate
Isosorbidi Mononitras
Medocor
Monicor
Mono corax
Monocedocard
Monocord
Monodur durules
Monoket
Monolong
Monomax
Mononit
Mononitrate d'Isosorbide
Mononitrato de Isosorbida
Monopront
Monosorb xl 60
Monosorbitrate
Monosordil
Nitramin
Olicard
Orasorbil
Pertil
Promocard
Sigacora
Sorbimon
Turimonit
Uniket
Vasdilat
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Isosorbide Mononitratetablet10 mg/1oralPhysicians Total Care, Inc.2012-07-18Not applicableUs
Isosorbide Mononitratetablet20 mg/1oralCarilion Materials Management1993-06-30Not applicableUs
Isosorbide Mononitratetablet20 mg/1oralKremers Urban Pharmaceuticals Inc.1993-06-30Not applicableUs
Isosorbide Mononitratetablet10 mg/1oralKremers Urban Pharmaceuticals Inc.1993-06-30Not applicableUs
Monokettablet20 mg/1oralKremers Urban Pharmaceuticals Inc.1993-06-30Not applicableUs
Monokettablet10 mg/1oralKremers Urban Pharmaceuticals Inc.1993-06-30Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Imdurtablet, extended release120 mg/1oralSchering Corporation2006-01-05Not applicableUs
Imdurtablet, extended release60 mg/1oralSchering Corporation2006-01-05Not applicableUs
Imdurtablet, extended release30 mg/1oralSchering Corporation2006-01-05Not applicableUs
Isosorbidetablet, film coated, extended release60 mg/1oralCardinal Health2006-03-302015-12-29Us
Isosorbidetablet, film coated, extended release30 mg/1oralCardinal Health2006-03-302015-12-29Us
Isosorbidetablet, film coated, extended release60 mg/1oralREMEDYREPACK INC.2013-05-29Not applicableUs
Isosorbidetablet, film coated, extended release30 mg/1oralCarilion Materials Management2006-03-30Not applicableUs
Isosorbidetablet, film coated, extended release30 mg/1oralREMEDYREPACK INC.2013-05-15Not applicableUs
Isosorbidetablet, film coated, extended release60 mg/1oralWest Ward Pharmaceuticals Corp2006-03-30Not applicableUs
Isosorbidetablet, extended release30 mg/1oralREMEDYREPACK INC.2012-09-17Not applicableUs
Isosorbidetablet, film coated, extended release30 mg/1oralWest Ward Pharmaceuticals Corp2006-03-30Not applicableUs
Isosorbide Mononitratetablet, extended release30 mg/1oralPhysicians Total Care, Inc.2000-11-27Not applicableUs
Isosorbide Mononitratetablet, extended release60 mg/1oralAv Pak2012-12-13Not applicableUs
Isosorbide Mononitratetablet120 mg/1oralZydus Pharmaceuticals (USA) Inc.2013-12-19Not applicableUs
Isosorbide Mononitratetablet60 mg/1oralZydus Pharmaceuticals (USA) Inc.2013-12-19Not applicableUs
Isosorbide Mononitratetablet, extended release30 mg/1oralAv Pak2012-12-13Not applicableUs
Isosorbide Mononitratetablet, extended release30 mg/1oralbryant ranch prepack1998-10-30Not applicableUs
Isosorbide Mononitratetablet, extended release120 mg/1oralRebel Distributors Corp1998-10-30Not applicableUs
Isosorbide Mononitratetablet, extended release30 mg/1oralLake Erie Medical DBA Quality Care Products LLC1998-10-30Not applicableUs
Isosorbide Mononitratetablet, extended release30 mg/1oralMajor Pharmaceuticals2015-01-05Not applicableUs
Isosorbide Mononitratetablet, extended release60 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-06-03Not applicableUs
Isosorbide Mononitratetablet, extended release120 mg/1oralQualitest Pharmaceuticals2010-08-11Not applicableUs
Isosorbide Mononitratetablet, extended release60 mg/1oralCardinal Health2013-02-15Not applicableUs
Isosorbide Mononitratetablet30 mg/1oralZydus Pharmaceuticals (USA) Inc.2013-12-19Not applicableUs
Isosorbide Mononitratetablet, extended release120 mg/1oralAphena Pharma Solutions Tennessee, Llc1998-10-30Not applicableUs
Isosorbide Mononitratetablet, extended release120 mg/1oralKremers Urban Pharmaceuticals Inc.1998-10-30Not applicableUs
Isosorbide Mononitratetablet, extended release30 mg/1oralRebel Distributors Corp1998-10-30Not applicableUs
Isosorbide Mononitratetablet, extended release30 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-06-03Not applicableUs
Isosorbide Mononitratetablet, extended release60 mg/1oralQualitest Pharmaceuticals2010-08-11Not applicableUs
Isosorbide Mononitratetablet, extended release30 mg/1oralCardinal Health2013-02-15Not applicableUs
Isosorbide Mononitratetablet, extended release60 mg/1oralMc Kesson Contract Packaging2013-06-13Not applicableUs
Isosorbide Mononitratetablet, extended release60 mg/1oralPd Rx Pharmaceuticals, Inc.1998-10-30Not applicableUs
Isosorbide Mononitratetablet, extended release30 mg/1oralKremers Urban Pharmaceuticals Inc.1998-10-30Not applicableUs
Isosorbide Mononitratetablet, extended release120 mg/1oralTorrent Pharmaceuticals Limited2011-06-03Not applicableUs
Isosorbide Mononitratetablet, extended release60 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-08-11Not applicableUs
Isosorbide Mononitratetablet, extended release30 mg/1oralQualitest Pharmaceuticals2010-08-11Not applicableUs
Isosorbide Mononitratetablet, extended release30 mg/1oralCardinal Health2011-06-03Not applicableUs
Isosorbide Mononitratetablet, extended release60 mg/1oralREMEDYREPACK INC.2013-05-23Not applicableUs
Isosorbide Mononitratetablet, extended release60 mg/1oralUnit Dose Services2010-06-07Not applicableUs
Isosorbide Mononitratetablet, extended release30 mg/1oralMc Kesson Contract Packaging2013-06-13Not applicableUs
Isosorbide Mononitratetablet, extended release60 mg/1oralAmerican Health Packaging2013-02-15Not applicableUs
Isosorbide Mononitratetablet, extended release30 mg/1oralLake Erie Medical DBA Quality Care Products LLC2013-06-13Not applicableUs
Isosorbide Mononitratetablet, extended release60 mg/1oralKremers Urban Pharmaceuticals Inc.1998-10-30Not applicableUs
Isosorbide Mononitratetablet, extended release60 mg/1oralTorrent Pharmaceuticals Limited2011-06-03Not applicableUs
Isosorbide Mononitratetablet, extended release30 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-08-11Not applicableUs
Isosorbide Mononitratetablet10 mg/1oralActavis Pharma, Inc.1998-10-30Not applicableUs
Isosorbide Mononitratetablet, extended release60 mg/1oralCardinal Health1998-10-30Not applicableUs
Isosorbide Mononitratetablet, extended release30 mg/1oralAmerican Health Packaging2013-02-15Not applicableUs
Isosorbide Mononitratetablet, extended release60 mg/1oralLake Erie Medical DBA Quality Care Products LLC1998-10-30Not applicableUs
Isosorbide Mononitratetablet, extended release60 mg/1oralREMEDYREPACK INC.2015-11-12Not applicableUs
Isosorbide Mononitratetablet, extended release30 mg/1oralTorrent Pharmaceuticals Limited2011-06-03Not applicableUs
Isosorbide Mononitratetablet20 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1998-10-30Not applicableUs
Isosorbide Mononitratetablet20 mg/1oralActavis Pharma, Inc.1998-10-30Not applicableUs
Isosorbide Mononitratetablet, extended release30 mg/1oralCardinal Health1998-10-30Not applicableUs
Isosorbide Mononitratetablet, extended release30 mg/1oralREMEDYREPACK INC.2013-05-30Not applicableUs
Isosorbide Mononitratetablet, extended release30 mg/1oralUnit Dose Services1998-10-30Not applicableUs
Isosorbide Mononitratetablet, extended release60 mg/1oralMc Kesson Contract Packaging2013-02-28Not applicableUs
Isosorbide Mononitratetablet10 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1998-10-30Not applicableUs
Isosorbide Mononitratetablet, coated20 mg/1oralWest ward Pharmaceutical Corp2000-10-05Not applicableUs
Isosorbide Mononitratetablet, extended release60 mg/1oralCardinal Health2010-09-07Not applicableUs
Isosorbide Mononitratetablet20 mg/1oralREMEDYREPACK INC.2013-03-18Not applicableUs
Isosorbide Mononitratetablet, extended release30 mg/1oralMc Kesson Contract Packaging2013-03-28Not applicableUs
Isosorbide Mononitratetablet, extended release30 mg/1oralAphena Pharma Solutions Tennessee, Llc1998-10-30Not applicableUs
Isosorbide Mononitratetablet, extended release30 mg/1oralREMEDYREPACK INC.2013-03-18Not applicableUs
Isosorbide Mononitratetablet, extended release30 mg/1oralREMEDYREPACK INC.2015-06-15Not applicableUs
Isosorbide Mononitratetablet, extended release60 mg/1oralBlenheim Pharmacal, Inc.2013-11-15Not applicableUs
Isosorbide Mononitratetablet, film coated, extended release30 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2006-03-30Not applicableUs
Isosorbide Mononitratetablet, extended release30 mg/1oralCardinal Health2010-09-07Not applicableUs
Isosorbide Mononitratetablet, film coated, extended release60 mg/1oralMc Kesson Contract Packaging2011-11-28Not applicableUs
Isosorbide Mononitratetablet, extended release60 mg/1oralAphena Pharma Solutions Tennessee, Llc1998-10-30Not applicableUs
Isosorbide Mononitratetablet, extended release60 mg/1oralHeritage Pharmaceuticals Inc.2010-06-07Not applicableUs
Isosorbide Mononitratetablet, extended release60 mg/1oralSt Marys Medical Park Pharmacy2013-05-15Not applicableUs
Isosorbide Mononitratetablet, extended release120 mg/1oralMajor Pharmaceuticals2015-01-05Not applicableUs
Isosorbide Mononitratetablet, film coated, extended release60 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2006-03-30Not applicableUs
Isosorbide Mononitratetablet, extended release60 mg/1oralPhysicians Total Care, Inc.2000-11-27Not applicableUs
Isosorbide Mononitratetablet, extended release120 mg/1oralAv Pak2014-04-28Not applicableUs
Isosorbide Mononitratetablet, extended release60 mg/1oralCarilion Materials Management1998-10-30Not applicableUs
Isosorbide Mononitratetablet, film coated, extended release30 mg/1oralMc Kesson Contract Packaging2011-09-13Not applicableUs
Isosorbide Mononitratetablet, extended release60 mg/1oralbryant ranch prepack1998-10-30Not applicableUs
Isosorbide Mononitratetablet, extended release60 mg/1oralRebel Distributors Corp1998-10-30Not applicableUs
Isosorbide Mononitratetablet, extended release30 mg/1oralSt Marys Medical Park Pharmacy2013-05-15Not applicableUs
Isosorbide Mononitratetablet, extended release60 mg/1oralMajor Pharmaceuticals2015-01-05Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ChemydurNot Available
CoranginNot Available
DilatrateNot Available
DurideNot Available
ElantanNot Available
EtimonisNot Available
ImodurNot Available
ImtrateNot Available
IsmexinNot Available
IsmoNot Available
IsmoxNot Available
IsomonNot Available
IsomonitNot Available
IsonormNot Available
MedocorNot Available
MonicorNot Available
MonitNot Available
Mono CoraxNot Available
Mono MackNot Available
MonocedocardNot Available
MonoclairNot Available
MonocordNot Available
Monodur DurulesNot Available
MonolongNot Available
MonomaxNot Available
MononitNot Available
MonoprontNot Available
MonosorbNot Available
MonosordilNot Available
MonotrateNot Available
NitraminNot Available
OlicardNot Available
OlicardinNot Available
OrasorbilNot Available
PertilNot Available
PlodinNot Available
PromocardNot Available
SigacoraNot Available
SolotrateNot Available
SorbimonNot Available
TurimonitNot Available
UniketNot Available
VasdilatNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIILX1OH63030
CAS number16051-77-7
WeightAverage: 191.1388
Monoisotopic: 191.042987025
Chemical FormulaC6H9NO6
InChI KeyInChIKey=YWXYYJSYQOXTPL-SLPGGIOYSA-N
InChI
InChI=1S/C6H9NO6/c8-3-1-11-6-4(13-7(9)10)2-12-5(3)6/h3-6,8H,1-2H2/t3-,4+,5+,6+/m0/s1
IUPAC Name
(3R,3aS,6S,6aR)-6-hydroxy-hexahydrofuro[3,2-b]furan-3-yl nitrate
SMILES
[H][C@]12OC[C@@H](O[N+]([O-])=O)[C@@]1([H])OC[C@@H]2O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as isosorbides. These are organic polycyclic compounds containing an isosorbide(1,4-Dianhydrosorbitol) moiety, which consists of two -oxolan-3-ol rings.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassFurofurans
Sub ClassIsosorbides
Direct ParentIsosorbides
Alternative Parents
Substituents
  • Isosorbide
  • Alkyl nitrate
  • Oxolane
  • Organic nitrate
  • Nitrate ester
  • Organic nitro compound
  • Secondary alcohol
  • Organic nitric acid or derivatives
  • Oxacycle
  • Organic 1,3-dipolar compound
  • Allyl-type 1,3-dipolar organic compound
  • Ether
  • Dialkyl ether
  • Hydrocarbon derivative
  • Organic salt
  • Organooxygen compound
  • Alcohol
  • Organic zwitterion
  • Aliphatic heteropolycyclic compound
Molecular FrameworkAliphatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the prevention of angina pectoris due to coronary artery disease and the treatment of acute and chronic angina pectoris, hypertension, and myocardial infarction.
PharmacodynamicsIsosorbide-5-mononitrate, the long-acting metabolite of isosorbide dinitrate, is used as a vasodilatory agent in the management of angina pectoris. By dilating the vessels, it lowers the blood pressure and reduces the left ventricular preload and afterload, therefore, leads to a reduction of myocardial oxygen requirement.
Mechanism of actionSimilar to other nitrites and organic nitrates, Isosorbide Mononitrate is converted to nitric oxide (NO), an active intermediate compound which activates the enzyme guanylate cyclase (Atrial natriuretic peptide receptor A). This stimulates the synthesis of cyclic guanosine 3',5'-monophosphate (cGMP) which then activates a series of protein kinase-dependent phosphorylations in the smooth muscle cells, eventually resulting in the dephosphorylation of the myosin light chain of the smooth muscle fiber. The subsequent release of calcium ions results in the relaxation of the smooth muscle cells and vasodilation.
Related Articles
Absorption100%
Volume of distribution
  • 0.6 to 0.7 L/kg
Protein binding5%
Metabolism

Hepatic

Route of eliminationIsosorbide mononitrate is primarily metabolized by the liver, but unlike oral isosorbide dinitrate, it is not subject to first-pass metabolism. Isosorbide mononitrate is cleared by denitration to isosorbide and glucuronidation as the mononitrate, with 96% of the administered dose excreted in the urine within 5 days and only about 1% eliminated in the feces. At least six different compounds have been detected in urine, with about 2% of the dose excreted as the unchanged drug and at least five metabolites.
Half life5 hours
Clearance
  • 120–122 mL/min [Single dose of 60 mg PO]
  • 151–187 mL/min [Single dose of extended-release tablet 60 mg PO]
  • 132-151 mL/min [Multiple doses of extended release tablet 60 mg PO]
  • 119-140 mL/min [Multiple doses of extended release tablet 120 mg PO]
ToxicitySymptoms of overdose include vasodilatation, venous pooling, reduced cardiac output, and hypotension. There are no data suggesting what dose of isosorbide mononitrate is likely to be life-threatening in humans. In rats and mice, there is significant lethality at doses of 2000 mg/kg and 3000 mg/kg, respectively.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9156
Blood Brain Barrier+0.9355
Caco-2 permeable-0.579
P-glycoprotein substrateNon-substrate0.7621
P-glycoprotein inhibitor INon-inhibitor0.7159
P-glycoprotein inhibitor IINon-inhibitor0.9116
Renal organic cation transporterNon-inhibitor0.8563
CYP450 2C9 substrateNon-substrate0.8674
CYP450 2D6 substrateNon-substrate0.8613
CYP450 3A4 substrateSubstrate0.5357
CYP450 1A2 substrateNon-inhibitor0.8532
CYP450 2C9 inhibitorNon-inhibitor0.8769
CYP450 2D6 inhibitorNon-inhibitor0.9106
CYP450 2C19 inhibitorNon-inhibitor0.8469
CYP450 3A4 inhibitorNon-inhibitor0.9471
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9596
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.7696
BiodegradationReady biodegradable0.8359
Rat acute toxicity2.0753 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.5741
hERG inhibition (predictor II)Non-inhibitor0.9304
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Schering plough corp
  • Actavis elizabeth llc
  • Brightstone pharma inc
  • Dexcel ltd
  • Elan pharmaceutical research corp
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Kremers urban co
  • Kv pharmaceutical co
  • Vintage pharmaceuticals inc
  • West ward pharmaceutical corp
  • Promius pharma llc
  • Teva pharmaceuticals usa inc
  • Schwarz gmbh
Packagers
Dosage forms
FormRouteStrength
Tablet, extended releaseoral120 mg/1
Tablet, extended releaseoral30 mg/1
Tablet, extended releaseoral60 mg/1
Tabletoral10 mg/1
Tabletoral120 mg/1
Tabletoral20 mg/1
Tabletoral30 mg/1
Tabletoral60 mg/1
Tablet, coatedoral20 mg/1
Tablet, film coated, extended releaseoral30 mg/1
Tablet, film coated, extended releaseoral60 mg/1
Prices
Unit descriptionCostUnit
Imdur er 120 mg tablet4.19USD tablet
Imdur 120 mg 24 Hour tablet3.15USD tablet
Imdur 60 mg 24 Hour tablet3.11USD tablet
Imdur er 60 mg tablet2.99USD tablet
Imdur 30 mg 24 Hour tablet2.87USD tablet
Imdur er 30 mg tablet2.85USD tablet
Monoket 20 mg tablet2.65USD tablet
Ismo 20 mg tablet2.1USD tablet
Monoket 10 mg tablet1.75USD tablet
Isosorbide Mononitrate CR 60 mg 24 Hour tablet1.48USD tablet
Isosorbide Mononitrate CR 30 mg 24 Hour tablet1.16USD tablet
Isosorbide Mononitrate 20 mg tablet0.78USD tablet
Isosorbide Mononitrate 10 mg tablet0.74USD tablet
Imdur 60 mg Extended-Release Tablet0.74USD tablet
Isosorbide mn 20 mg tablet0.72USD tablet
Isosorbide mn 10 mg tablet0.71USD tablet
Apo-Ismn 60 mg Extended-Release Tablet0.42USD tablet
Pms-Ismn 60 mg Extended-Release Tablet0.42USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point88-91 °CNot Available
water solubility1.07E+005 mg/LNot Available
logP-0.15SANGSTER (1993)
Predicted Properties
PropertyValueSource
Water Solubility57.0 mg/mLALOGPS
logP-0.74ALOGPS
logP-0.48ChemAxon
logS-0.53ALOGPS
pKa (Strongest Acidic)13.34ChemAxon
pKa (Strongest Basic)-3.5ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area93.74 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity38.08 m3·mol-1ChemAxon
Polarizability15.85 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesC01DA14
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (217 KB)
MSDSDownload (66.5 KB)
Interactions
Drug Interactions
Drug
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Isosorbide Mononitrate.
AprepitantThe serum concentration of Isosorbide Mononitrate can be increased when it is combined with Aprepitant.
BexaroteneThe serum concentration of Isosorbide Mononitrate can be decreased when it is combined with Bexarotene.
BosentanThe serum concentration of Isosorbide Mononitrate can be decreased when it is combined with Bosentan.
ButabarbitalButabarbital may increase the hypotensive activities of Isosorbide Mononitrate.
ButethalButethal may increase the hypotensive activities of Isosorbide Mononitrate.
ConivaptanThe serum concentration of Isosorbide Mononitrate can be increased when it is combined with Conivaptan.
DabrafenibThe serum concentration of Isosorbide Mononitrate can be decreased when it is combined with Dabrafenib.
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Isosorbide Mononitrate.
DapsoneThe risk or severity of adverse effects can be increased when Dapsone is combined with Isosorbide Mononitrate.
DasatinibThe serum concentration of Isosorbide Mononitrate can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Isosorbide Mononitrate can be decreased when it is combined with Deferasirox.
DuloxetineIsosorbide Mononitrate may increase the orthostatic hypotensive activities of Duloxetine.
EthanolEthanol may increase the vasodilatory activities of Isosorbide Mononitrate.
FluconazoleThe metabolism of Isosorbide Mononitrate can be decreased when combined with Fluconazole.
FosaprepitantThe serum concentration of Isosorbide Mononitrate can be increased when it is combined with Fosaprepitant.
Fusidic AcidThe serum concentration of Isosorbide Mononitrate can be increased when it is combined with Fusidic Acid.
HeptabarbitalHeptabarbital may increase the hypotensive activities of Isosorbide Mononitrate.
HexobarbitalHexobarbital may increase the hypotensive activities of Isosorbide Mononitrate.
IdelalisibThe serum concentration of Isosorbide Mononitrate can be increased when it is combined with Idelalisib.
IvacaftorThe serum concentration of Isosorbide Mononitrate can be increased when it is combined with Ivacaftor.
LevodopaIsosorbide Mononitrate may increase the orthostatic hypotensive activities of Levodopa.
LuliconazoleThe serum concentration of Isosorbide Mononitrate can be increased when it is combined with Luliconazole.
MethohexitalMethohexital may increase the hypotensive activities of Isosorbide Mononitrate.
MifepristoneThe serum concentration of Isosorbide Mononitrate can be increased when it is combined with Mifepristone.
MitotaneThe serum concentration of Isosorbide Mononitrate can be decreased when it is combined with Mitotane.
MolsidomineMolsidomine may increase the hypotensive activities of Isosorbide Mononitrate.
NelfinavirThe metabolism of Isosorbide Mononitrate can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Isosorbide Mononitrate can be increased when it is combined with Netupitant.
NicorandilNicorandil may increase the hypotensive activities of Isosorbide Mononitrate.
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Isosorbide Mononitrate.
PalbociclibThe serum concentration of Isosorbide Mononitrate can be increased when it is combined with Palbociclib.
PentobarbitalPentobarbital may increase the hypotensive activities of Isosorbide Mononitrate.
PhenytoinThe metabolism of Isosorbide Mononitrate can be increased when combined with Phenytoin.
PrilocaineThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Prilocaine.
PrimidonePrimidone may increase the hypotensive activities of Isosorbide Mononitrate.
RiociguatIsosorbide Mononitrate may increase the hypotensive activities of Riociguat.
RisperidoneIsosorbide Mononitrate may increase the hypotensive activities of Risperidone.
RosiglitazoneThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Rosiglitazone.
SecobarbitalSecobarbital may increase the hypotensive activities of Isosorbide Mononitrate.
SiltuximabThe serum concentration of Isosorbide Mononitrate can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Isosorbide Mononitrate can be increased when it is combined with Simeprevir.
Sodium NitriteThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Sodium Nitrite.
St. John's WortThe serum concentration of Isosorbide Mononitrate can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Isosorbide Mononitrate can be increased when it is combined with Stiripentol.
TadalafilTadalafil may increase the vasodilatory activities of Isosorbide Mononitrate.
TocilizumabThe serum concentration of Isosorbide Mononitrate can be decreased when it is combined with Tocilizumab.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Isosorbide Mononitrate.
VardenafilVardenafil may increase the vasodilatory activities of Isosorbide Mononitrate.
Food Interactions
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inducer
General Function:
Heme binding
Specific Function:
Has guanylyl cyclase on binding to the beta-1 subunit.Isoform 2 acts as a negative regulator of guanylyl cyclase activity as it forms non-functional heterodimers with the beta subunits.
Gene Name:
GUCY1A2
Uniprot ID:
P33402
Molecular Weight:
81749.185 Da
References
  1. Moncada S, Palmer RM, Higgs EA: Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991 Jun;43(2):109-42. [PubMed:1852778 ]
  2. Mancuso C, Navarra P, Preziosi P: Roles of nitric oxide, carbon monoxide, and hydrogen sulfide in the regulation of the hypothalamic-pituitary-adrenal axis. J Neurochem. 2010 May;113(3):563-75. doi: 10.1111/j.1471-4159.2010.06606.x. Epub 2010 Jan 20. [PubMed:20089135 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:13